Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917554 | 0.89 | FDPS (0.41) | F2FDPSMDM2 | |
| SCHEMBL917421 | 0.89 | FDPS (0.41) | F2FDPSMDM2 | |
| SCHEMBL12201441 | 0.81 | LATS1 (0.49) | F2FDPSCTSDKMT2AL3MBTL1 | |
| SCHEMBL1608002 | 0.80 | ALDH1A1 (0.52) | CYP2D6L3MBTL1KDM4E | |
| SCHEMBL4825163 | 0.77 | CYP2D6 (0.59) | F2CYP2D6 | |
| SCHEMBL9100229 | 0.77 | MAPT (0.59) | KMT2AMEN1L3MBTL1KDM4E | |
| SCHEMBL8064544 | 0.74 | ALDH5A1 (0.38) | F2CYP2D6KDM4E | |
| SCHEMBL11407372 | 0.74 | CA2 (0.43) | KMT2A | |
| SCHEMBL18747641 | 0.73 | CA1 (0.60) | KMT2AMEN1BCHE | |
| SCHEMBL10231857 | 0.73 | BCHE (0.62) | MDM2L3MBTL1KDM4EBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | DALY THOMAS (US) | 2021-08-12 | — | — | US | disclosed |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2020-03-05 | — | — | US | disclosed |
| US-8334402-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC | 2012-12-18 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8034951-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC | 2011-10-11 | — | — | US | disclosed |
| US-20110137076-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2011-06-09 | — | — | US | disclosed |
| US-20100190993-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2010-07-29 | — | — | US | disclosed |
| US-20100190993-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2010-07-29 | — | — | US | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | disclosed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | disclosed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
| US-4067741-A | Hardening photographic layers containing silver halide with a 1-sulphonyl-4-amino-pyridinium salt | AGFA-GEVAERT, A.G. (DT) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190993-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | F2 1512/4885FDPS 4531/4885MDM2 4466/4885 |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | F2 1512/4885FDPS 4531/4885MDM2 4466/4885 |
| US-20110137076-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | F2 1512/4885FDPS 4531/4885MDM2 4466/4885 |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | F2 1602/4885FDPS 4470/4885MDM2 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.